📊 Full opportunity report: GLP-1 Stock And Pricing Across Pharmacies: What The Data Shows on IdeaNavigator AI — validation score, market gap, and execution plan.
Get smart everyday buys delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
TL;DR
IdeaNavigator AI proposes a pharmacy index that would track brand-name GLP-1 availability by dose and ZIP code alongside cash prices. The proposal describes a fragmented market but supplies no collected pharmacy dataset, so the scale of stockouts and price variation remains unverified.
IdeaNavigator AI has proposed a GLP-1 pharmacy index that would show patients where specific doses may be available and compare cash prices by ZIP code, while licensing the same data to health care businesses. The proposal addresses a possible shift from nationwide shortage concerns to local dose availability and fragmented pricing, but it does not provide collected pharmacy data or evidence that the tool has been built.
The proposed consumer service would cover four brand-name medicines: Ozempic, Wegovy, Zepbound and Mounjaro. Users would search by drug, dose and ZIP code for reported availability and cash prices. IdeaNavigator AI suggests combining public prices from manufacturer direct channels, Costco and Walmart with a discount-price layer and reports submitted by consumers. It also proposes alerts when a particular dose becomes available.
The business model pairs a free consumer finder with a paid availability and pricing feed or dashboard. Potential customers named in the proposal include telehealth prescribers, employers and benefits teams, pharmacy benefit managers, and brokers. The proposal also mentions possible referral fees from legitimate pharmacy or manufacturer-direct channels; it does not set out any signed partnerships, prices for the data service, or operating arrangements.
IdeaNavigator AI proposes testing the idea in one metropolitan area over 60 days. Its stated validation targets are at least 200 consumer stock reports and paid pilots or letters of intent from at least two business prospects. These are proposed thresholds, not reported results. No metro area, test launch date, named prospective buyer or completed consumer survey is provided.
Dose Access Meets Price Fragmentation
If patients cannot readily compare a specific dose across pharmacies and direct-purchase channels, a national shortage status may not answer the practical question of where to find that dose today. A normalized index could make local reports and listed cash prices easier to compare, while helping prescribers and benefits teams see availability across locations. Those are potential uses described by the proposal, not demonstrated outcomes.
For patients paying without insurance, the proposal says monthly cash prices can range from about $199 to more than $1,000, depending on product and seller. That broad range signals why comparisons could matter, but the proposal does not specify which medicines, doses, dates, or price terms underpin it. Prices may depend on eligibility, dose, program rules and other conditions. Readers should not treat the figures as a verified, current quote for a particular prescription.
The business case also depends on whether the data are reliable enough for buyers to pay for. A feed that confuses a consumer stock report with confirmed inventory could mislead users; a listed cash price may not be available to every patient. The proposal would need clear timestamps, pharmacy confirmation methods and eligibility details for its comparisons to be useful. It does not describe those methods yet.
From Shortages to Local Supply
The proposal says the FDA declared tirzepatide shortages resolved in December 2024 and semaglutide shortages resolved in February 2025. It frames the current challenge as uneven local supply and scattered pricing information. A resolved shortage listing does not, by itself, establish that every pharmacy has every dose available; however, no independent pharmacy-level inventory figures are supplied here to measure how often local gaps occur.
IdeaNavigator AI also points to manufacturer direct-purchase channels, retail options and the TrumpRx portal, which it dates to February 2026, as contributors to a more dispersed pricing landscape. It says deadlines related to compounding pushed compounders out of the market, but provides no details on the deadlines or their effects. The proposal further says employers report GLP-1 medicines account for roughly 20% of pharmacy spending. It does not identify the employers, reporting period, or spending measure, so that figure cannot establish how broadly the claim applies.
The index is presented as a response to this combination of changing supply and multiple purchase channels. Its core proposed feature is a normalized comparison for a medicine, dose and location at a particular time. That time-specific approach matters because a price listing and a stock report can become outdated; the proposal does not state how frequently information would be refreshed.
Inventory and Price Evidence
The proposal provides no live inventory feed, price sample, pharmacy list or historical dataset. It is not clear how many patients currently encounter dose-specific stockouts, how quickly reported availability changes, or whether a crowdsourced report could be verified. The stated cash-price range is not accompanied by a date, dose-by-dose breakdown, or eligibility terms.
It is also unclear whether pharmacies and direct channels would share inventory data, how the index would distinguish confirmed stock from user reports, and how often prices would be checked. No paying customers, signed pilots, letters of intent, referral agreements or product launch are identified. Until such evidence is available, the index remains a business proposal rather than a demonstrated service or market study.
A Metro Pilot Would Test Demand
The next step described by IdeaNavigator AI is to test a consumer search page and a separate business pitch with buyers in telehealth and employer benefits. The proposed 60-day targets—200 consumer reports and two paid pilots or letters of intent—would offer an initial signal of participation and buyer interest. Meeting those targets would not, by itself, prove that reports are accurate, that prices stay current, or that the service can work across the country.
Further evidence would be needed on reporting accuracy, update speed, price eligibility and whether prospective customers renew or expand paid use. No launch date or follow-up results have been announced in the material available for this report.
Source: IdeaNavigator AI
Key Questions
Has the GLP-1 pharmacy index launched?
No launch is reported. IdeaNavigator AI describes a proposed tool and a possible 60-day test, without giving a launch date or showing a working index.
Which medicines would the proposed index cover?
The proposed first version would cover Ozempic, Wegovy, Zepbound and Mounjaro, searchable by dose and ZIP code.
Are the cited cash prices verified current prices?
The proposal gives a range of about $199 to more than $1,000 per month, but does not provide dates, dose details or eligibility terms. It should not be read as a current quote for an individual prescription.
What would show whether the idea has traction?
The proposed metro test sets targets of 200 consumer stock reports and at least two paid pilots or letters of intent from business prospects within 60 days. No results against those targets are reported.
Source: IdeaNavigator AI
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
